Isabelle Desombere
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Isabelle Desombere has a total of 143 co-authors. Here are the top co-authors by number of shared publications:
- Els Duysburgh
Department of Epidemiology and Public Health, Sciensano, 1000 Brussels, Belgium
6 shared publications - Maria E. Goossens
Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium
5 shared publications - Arnaud Marchant
European Plotkin Institute for Vaccinology, Université Libre de Bruxelles, 900 Route de Lennik, 170 Anderlecht, Belgium; ULB Centre for Research in Immunology (U-CRI), Université Libre de Bruxelles, 8 Rue Adrienne Bolland, 6041 Gosselies, Belgium
4 shared publications - Kevin K. Arien
Virology Unit, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium
4 shared publications - Pieter Pannus
Scientific Direction Infectious Diseases in Humans, Sciensano, Brussels, Belgium
4 shared publications - An De Sutter
Department of Public Health and Primary Care, Faculty of Medicine and Health Sciences, Ghent University, 9000 Ghent, Belgium
3 shared publications
Latest Publications
- 27 March 2026
- Published by SAGE Publications in Journal of Human Lactation
The COVALAC Study: The Impact of COVID-19 Vaccination During Lactation on SARS-CoV-2-Specific Antibodies in Human Milk—A Prospective Cohort Study
Background: The COVID-19-pandemic prompted global vaccination campaigns, raising important questions about vaccine-induced immune responses in lactating women and the transfer of SARS-CoV-2-specific antibodies through human milk. This study investigated the presence of SARS-CoV-2-specific IgA and IgG antibodies in breastmilk for up to 6 months following COVID-19 vaccination and booster doses with either mRNA or adenoviral vector (AVV) vaccines. Method: The COVALAC-study was a prospective cohort study conducted in Belgium. Women were recruited between February and March 2021, followed for 180 days post-vaccination and 28 days post-booster. Breastmilk samples were collected at multiple timepoints and analyzed for IgA and IgG antibodies. Participants received either mRNA (BNT162b2, mRNA-127) or AVV (ChAdOx1 nCoV-19) vaccines. Antibody concentrations were measured using an in-house immunoassay, and analyses compared responses between vaccine types. Results: Of the 115 participants, 40% received BNT162b2, 4.3% mRNA-1273, and 55.7% ChAdOx1-S as their primary vaccination. Of these, 31 participants received an mRNA booster (11 homologous, 20 heterologous boosters). IgA and IgG antibody levels were monitored pre- and post-vaccination, showing a stronger antibody response after mRNA vaccination compared to AVV, after roughly 14 days (IgA receptor binding domain [RBD] 1.13 BAU/mil; 0.61–1.67; IgG RBD 2.56 BAU/mil; 0.76–4.71, up to 1 month, for most antibodies. Both homologous and heterologous boosters further increased antibody titers (IgA RBD 0,85 BAU/ml; 1.09–1.72). Conclusion: COVID-19 vaccination during lactating induces SARS-CoV-2 specific IgA and IgG antibodies in human milk. Antibody levels were higher following mRNA vaccination compared to AVV vaccination, with booster doses enhancing these levels further.
- 27 March 2026
- Published by SAGE Publications in Journal of Human Lactation
The COVALAC Study: The Impact of COVID-19 Vaccination During Lactation on SARS-CoV-2-Specific Antibodies in Human Milk—A Prospective Cohort Study
Background: The COVID-19-pandemic prompted global vaccination campaigns, raising important questions about vaccine-induced immune responses in lactating women and the transfer of SARS-CoV-2-specific antibodies through human milk. This study investigated the presence of SARS-CoV-2-specific IgA and IgG antibodies in breastmilk for up to 6 months following COVID-19 vaccination and booster doses with either mRNA or adenoviral vector (AVV) vaccines. Method: The COVALAC-study was a prospective cohort study conducted in Belgium. Women were recruited between February and March 2021, followed for 180 days post-vaccination and 28 days post-booster. Breastmilk samples were collected at multiple timepoints and analyzed for IgA and IgG antibodies. Participants received either mRNA (BNT162b2, mRNA-127) or AVV (ChAdOx1 nCoV-19) vaccines. Antibody concentrations were measured using an in-house immunoassay, and analyses compared responses between vaccine types. Results: Of the 115 participants, 40% received BNT162b2, 4.3% mRNA-1273, and 55.7% ChAdOx1-S as their primary vaccination. Of these, 31 participants received an mRNA booster (11 homologous, 20 heterologous boosters). IgA and IgG antibody levels were monitored pre- and post-vaccination, showing a stronger antibody response after mRNA vaccination compared to AVV, after roughly 14 days (IgA receptor binding domain [RBD] 1.13 BAU/mil; 0.61–1.67; IgG RBD 2.56 BAU/mil; 0.76–4.71, up to 1 month, for most antibodies. Both homologous and heterologous boosters further increased antibody titers (IgA RBD 0,85 BAU/ml; 1.09–1.72). Conclusion: COVID-19 vaccination during lactating induces SARS-CoV-2 specific IgA and IgG antibodies in human milk. Antibody levels were higher following mRNA vaccination compared to AVV vaccination, with booster doses enhancing these levels further.
- Open Access
Validation of a rapid SARS-CoV-2 antibody test in general practice
Objectives To validate a rapid serological test (RST) for SARS-CoV-2 antibodies used in seroprevalence studies in healthcare providers, including primary healthcare providers (PHCPs) in Belgium. Design A phase III validation study of the RST (OrientGene) within a prospective cohort study. Setting Primary care in Belgium. Participants Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages patients were eligible in the seroprevalence study. For the validation study, all participants who tested positive (376) on the RST at the first testing timepoint (T1) and a random sample of those who tested negative (790) and unclear (24) were included. Intervention At T2, 4 weeks later, PHCPs performed the RST with fingerprick blood (index test) immediately after providing a serum sample to be analysed for the presence of SARS-CoV-2 immunoglobulin G antibodies using a two-out-of-three assay (reference test). Primary and secondary outcome measures The RST accuracy was estimated using inverse probability weighting to correct for missing reference test data, and considering unclear RST results as negative for the sensitivity and positive for the specificity. Using these conservative estimates, the true seroprevalence was estimated both for T2 and RST-based prevalence values found in a cohort study with PHCPs in Belgium. Results 1073 paired tests (403 positive on the reference test) were included. A sensitivity of 73% (a specificity of 92%) was found considering unclear RST results as negative (positive). For an RST-based prevalence at T1 (13.9), T2 (24.9) and T7 (70.21), the true prevalence was estimated to be 9.1%, 25.9% and 95.7%, respectively. Conclusion The RST sensitivity (73%) and specificity (92%) make an RST-based seroprevalence below (above) 23% overestimate (underestimate) the true seroprevalence. Trial registration number NCT04779424.
Open AccessValidation of a rapid SARS-CoV-2 antibody test in general practice
Objectives To validate a rapid serological test (RST) for SARS-CoV-2 antibodies used in seroprevalence studies in healthcare providers, including primary healthcare providers (PHCPs) in Belgium. Design A phase III validation study of the RST (OrientGene) within a prospective cohort study. Setting Primary care in Belgium. Participants Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages patients were eligible in the seroprevalence study. For the validation study, all participants who tested positive (376) on the RST at the first testing timepoint (T1) and a random sample of those who tested negative (790) and unclear (24) were included. Intervention At T2, 4 weeks later, PHCPs performed the RST with fingerprick blood (index test) immediately after providing a serum sample to be analysed for the presence of SARS-CoV-2 immunoglobulin G antibodies using a two-out-of-three assay (reference test). Primary and secondary outcome measures The RST accuracy was estimated using inverse probability weighting to correct for missing reference test data, and considering unclear RST results as negative for the sensitivity and positive for the specificity. Using these conservative estimates, the true seroprevalence was estimated both for T2 and RST-based prevalence values found in a cohort study with PHCPs in Belgium. Results 1073 paired tests (403 positive on the reference test) were included. A sensitivity of 73% (a specificity of 92%) was found considering unclear RST results as negative (positive). For an RST-based prevalence at T1 (13.9), T2 (24.9) and T7 (70.21), the true prevalence was estimated to be 9.1%, 25.9% and 95.7%, respectively. Conclusion The RST sensitivity (73%) and specificity (92%) make an RST-based seroprevalence below (above) 23% overestimate (underestimate) the true seroprevalence. Trial registration number NCT04779424.
- Open Access
- 10 February 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (5) , 649-658
Humoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
- 10 February 2023
- Published by Elsevier in American Journal of Transplantation
- Vol. 23 (5) , 649-658
Open AccessHumoral and cellular immune correlates of protection against COVID-19 in kidney transplant recipients
- Open Access
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (3) , 994-995
Hybrid immunity to SARS-CoV-2 in kidney transplant recipients and hemodialysis patients
- 30 December 2022
- Published by Elsevier in American Journal of Transplantation
- Vol. 22 (3) , 994-995
Open AccessHybrid immunity to SARS-CoV-2 in kidney transplant recipients and hemodialysis patients
- Open Access
Prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
Objectives To estimate the prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers (PHCPs). Design Prospective cohort study with 12 months of follow-up. Setting Primary care in Belgium. Participants Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages (examines, tests, treats) patients were eligible. A convenience sample of 3648 eligible PHCPs from 2001 GP practices registered for this study (3044 and 604 to start in December 2020 and January 2021, respectively). 3390 PHCPs (92,9%) participated in their first testing time point (2820 and 565, respectively) and 2557 PHCPs (70,1%) in the last testing time point (December 2021). Interventions Participants were asked to perform a rapid serological test targeting IgM and IgG against the receptor binding domain of SARS-CoV-2 and to complete an online questionnaire at each of maximum eight testing time points. Primary and secondary outcome measures The prevalence, incidence and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination. Results Among all participants, 67% were women and 77% GPs. Median age was 43 years. The seroprevalence in December 2020 (before vaccination availability) was 15.1% (95% CI 13.5% to 16.6%), increased to 84.2% (95% CI 82.9% to 85.5%) in March 2021 (after vaccination availability) and reached 93.9% (95% CI 92.9% to 94.9%) in December 2021 (during booster vaccination availability and fourth (delta variant dominant) COVID-19 wave). Among not (yet) vaccinated participants the first monthly incidence of antibodies against SARS-CoV-2 was estimated to be 2.91% (95% CI 1.80% to 4.01%). The longevity of antibodies is higher in PHCPs with self-reported COVID-19 infection. Conclusions This study confirms that occupational health measures provided sufficient protection when managing patients. High uptake of vaccination resulted in high seroprevalence of SARS-CoV-2 antibodies in PHCPs in Belgium. Longevity of antibodies was supported by booster vaccination and virus circulation. Trial registration number NCT04779424.
Open AccessPrevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
Objectives To estimate the prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers (PHCPs). Design Prospective cohort study with 12 months of follow-up. Setting Primary care in Belgium. Participants Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages (examines, tests, treats) patients were eligible. A convenience sample of 3648 eligible PHCPs from 2001 GP practices registered for this study (3044 and 604 to start in December 2020 and January 2021, respectively). 3390 PHCPs (92,9%) participated in their first testing time point (2820 and 565, respectively) and 2557 PHCPs (70,1%) in the last testing time point (December 2021). Interventions Participants were asked to perform a rapid serological test targeting IgM and IgG against the receptor binding domain of SARS-CoV-2 and to complete an online questionnaire at each of maximum eight testing time points. Primary and secondary outcome measures The prevalence, incidence and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination. Results Among all participants, 67% were women and 77% GPs. Median age was 43 years. The seroprevalence in December 2020 (before vaccination availability) was 15.1% (95% CI 13.5% to 16.6%), increased to 84.2% (95% CI 82.9% to 85.5%) in March 2021 (after vaccination availability) and reached 93.9% (95% CI 92.9% to 94.9%) in December 2021 (during booster vaccination availability and fourth (delta variant dominant) COVID-19 wave). Among not (yet) vaccinated participants the first monthly incidence of antibodies against SARS-CoV-2 was estimated to be 2.91% (95% CI 1.80% to 4.01%). The longevity of antibodies is higher in PHCPs with self-reported COVID-19 infection. Conclusions This study confirms that occupational health measures provided sufficient protection when managing patients. High uptake of vaccination resulted in high seroprevalence of SARS-CoV-2 antibodies in PHCPs in Belgium. Longevity of antibodies was supported by booster vaccination and virus circulation. Trial registration number NCT04779424.
- Open Access
The prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
Objectives: To estimate the prevalence, incidence, and longevity of antibodies against SARS-CoV-2 among primary healthcare providers (PHCPs). Design: Prospective cohort study with 12 months of follow-up. Setting: Primary care in Belgium Participants: Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages (examines, tests, treats) patients were eligible. A convenience sample of 3,648 eligible PHCPs from 2,001 GP practices registered for this study (3,044 and 604 to start in December 2020 and January 2021, respectively). 3,390 PHCPs (92,9%) participated in their first testing timepoint (2,820 and 565, respectively) and 2,557 PHCPs (70,1%) in the last testing timepoint (December 2021). Interventions: Participants were asked to perform a rapid serological test (RST) targeting IgM and IgG against the receptor binding domain (RBD) of SARS-CoV-2 and to complete an online questionnaire at each of maximum 8 testing timepoints. Primary and secondary outcome measures: The prevalence, incidence, and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination. Results: Among all participants, 67% were women and 77% GPs. Median age was 43 years. The seroprevalence in December 2020 (before vaccination availability) was 15.1% (95% CI: 13.5% to 16.6%), increased to 84.2% (95% CI: 82.9% to 85.5%) in March 2021 (after vaccination availability) and reached 93.9% (95% CI: 92.9% to 94.9%) in December 2021 (during booster vaccination availability and fourth (delta variant dominant) covid wave). Among not (yet) vaccinated participants the first monthly incidence of antibodies against SARS-CoV-2 was estimated to be 2.91% (95% CI: 1.80% to 4.01%). The longevity of antibodies is higher in PHCPs with self-reported COVID-19 infection. Conclusions: This study confirms that occupational health measures provided sufficient protection when managing patients. High uptake of vaccination resulted in high seroprevalence of SARS-CoV-2 antibodies in PHCPs in Belgium. Longevity of antibodies was supported by booster vaccination and virus circulation. Registration: Trial registration number: NCT04779424 Strengths and limitations of this study: This large cohort study with 12 months follow-up could provide precise estimates of the prevalence and incidence of antibodies against SARS-CoV-2 among primary health care providers (PHCPs) at national and regional level in Belgium. The rapid serological test (RST) used targets IgM and IgG against the receptor binding domain of SARS-CoV-2 and could therefore also assess the antibody response after vaccination, and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination, but cannot distinguish between both. The results in PHCPs could be compared to that of the general population and other population groups, e.g. health care workers in hospitals and nursing homes. The use of a convenience sample, missing data points and reduced RST accuracy when performed and interpreted by many different participants could limit the validity of the study results.
Open AccessThe prevalence, incidence and longevity of antibodies against SARS-CoV-2 among primary healthcare providers in Belgium: a prospective cohort study with 12 months of follow-up
Objectives: To estimate the prevalence, incidence, and longevity of antibodies against SARS-CoV-2 among primary healthcare providers (PHCPs). Design: Prospective cohort study with 12 months of follow-up. Setting: Primary care in Belgium Participants: Any general practitioner (GP) working in primary care in Belgium and any other PHCP from the same GP practice who physically manages (examines, tests, treats) patients were eligible. A convenience sample of 3,648 eligible PHCPs from 2,001 GP practices registered for this study (3,044 and 604 to start in December 2020 and January 2021, respectively). 3,390 PHCPs (92,9%) participated in their first testing timepoint (2,820 and 565, respectively) and 2,557 PHCPs (70,1%) in the last testing timepoint (December 2021). Interventions: Participants were asked to perform a rapid serological test (RST) targeting IgM and IgG against the receptor binding domain (RBD) of SARS-CoV-2 and to complete an online questionnaire at each of maximum 8 testing timepoints. Primary and secondary outcome measures: The prevalence, incidence, and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination. Results: Among all participants, 67% were women and 77% GPs. Median age was 43 years. The seroprevalence in December 2020 (before vaccination availability) was 15.1% (95% CI: 13.5% to 16.6%), increased to 84.2% (95% CI: 82.9% to 85.5%) in March 2021 (after vaccination availability) and reached 93.9% (95% CI: 92.9% to 94.9%) in December 2021 (during booster vaccination availability and fourth (delta variant dominant) covid wave). Among not (yet) vaccinated participants the first monthly incidence of antibodies against SARS-CoV-2 was estimated to be 2.91% (95% CI: 1.80% to 4.01%). The longevity of antibodies is higher in PHCPs with self-reported COVID-19 infection. Conclusions: This study confirms that occupational health measures provided sufficient protection when managing patients. High uptake of vaccination resulted in high seroprevalence of SARS-CoV-2 antibodies in PHCPs in Belgium. Longevity of antibodies was supported by booster vaccination and virus circulation. Registration: Trial registration number: NCT04779424 Strengths and limitations of this study: This large cohort study with 12 months follow-up could provide precise estimates of the prevalence and incidence of antibodies against SARS-CoV-2 among primary health care providers (PHCPs) at national and regional level in Belgium. The rapid serological test (RST) used targets IgM and IgG against the receptor binding domain of SARS-CoV-2 and could therefore also assess the antibody response after vaccination, and longevity of antibodies against SARS-CoV-2 both after natural infection and after vaccination, but cannot distinguish between both. The results in PHCPs could be compared to that of the general population and other population groups, e.g. health care workers in hospitals and nursing homes. The use of a convenience sample, missing data points and reduced RST accuracy when performed and interpreted by many different participants could limit the validity of the study results.
- Open Access
Prevalence of Anti-SARS-CoV-2 Antibodies and Potential Determinants among the Belgian Adult Population: Baseline Results of a Prospective Cohort Study
The prevalence of anti-SARS-CoV-2 antibodies and potential determinants were assessed in a random sample representative of the Belgian adult population. In total, 14,201 individuals (≥18 years) were invited by mail to provide saliva via an Oracol® swab. Survey weights were applied, and potential determinants were estimated using multivariable logistic regressions. Between March and August 2021, 2767 individuals participated in the first data collection. During this period, which coincided with the onset of the vaccination campaign, the seroprevalence in the population increased from 25.2% in March/April to 78.1% in July. Among the vaccinated there was an increase from 74,2% to 98.8%; among the unvaccinated, the seroprevalence remained stable (around 17%). Among the vaccinated, factors significantly associated with the presence of antibodies were: having at least one chronic disease (ORa 0.22 (95% CI 0.08–0.62)), having received an mRNA-type vaccine (ORa 5.38 (95% CI 1.72–16.80)), and having received an influenza vaccine in 2020–2021 (ORa 3.79 (95% CI 1.30–11.07)). Among the unvaccinated, having a non-O blood type (ORa 2.00 (95% CI 1.09–3.67)) and having one or more positive COVID-19 tests (ORa 11.04 (95% CI 4.69–26.02)) were significantly associated. This study provides a better understanding of vaccine- and/or natural-induced presence of anti-SARS-CoV-2 antibodies and factors that are associated with this presence.
Open AccessPrevalence of Anti-SARS-CoV-2 Antibodies and Potential Determinants among the Belgian Adult Population: Baseline Results of a Prospective Cohort Study
The prevalence of anti-SARS-CoV-2 antibodies and potential determinants were assessed in a random sample representative of the Belgian adult population. In total, 14,201 individuals (≥18 years) were invited by mail to provide saliva via an Oracol® swab. Survey weights were applied, and potential determinants were estimated using multivariable logistic regressions. Between March and August 2021, 2767 individuals participated in the first data collection. During this period, which coincided with the onset of the vaccination campaign, the seroprevalence in the population increased from 25.2% in March/April to 78.1% in July. Among the vaccinated there was an increase from 74,2% to 98.8%; among the unvaccinated, the seroprevalence remained stable (around 17%). Among the vaccinated, factors significantly associated with the presence of antibodies were: having at least one chronic disease (ORa 0.22 (95% CI 0.08–0.62)), having received an mRNA-type vaccine (ORa 5.38 (95% CI 1.72–16.80)), and having received an influenza vaccine in 2020–2021 (ORa 3.79 (95% CI 1.30–11.07)). Among the unvaccinated, having a non-O blood type (ORa 2.00 (95% CI 1.09–3.67)) and having one or more positive COVID-19 tests (ORa 11.04 (95% CI 4.69–26.02)) were significantly associated. This study provides a better understanding of vaccine- and/or natural-induced presence of anti-SARS-CoV-2 antibodies and factors that are associated with this presence.